Non-coding RNA: a potential biomarker and therapeutic target for sepsis

Accumulating evidence has documented the significance of miR-149 as a promising tumor-suppressive non-coding RNA that plays critical roles in regulating genes involved in cancer growth and metastasis. Notably, the ability of miR-149 to be utilized as a potential biomarker in the diagnosis/prognosis or a therapeutic target has also been explored using various cellular and preclinical models, as well as in clinical settings of lung cancer. While the applicability of miR-149 in assessing tumor progression has been suggested, its potential in predicting treatment outcomes is needed to be verified in diverse settings of lung cancer patients. The current review presents an overview of the functional significance of miR-149 with ongoing challenges in non-small cell lung cancer.

Download Full-text

Focally amplified long non-coding RNA in epithelial cancer as a potential biomarker and therapeutic target

Biomarkers in Medicine ◽

10.2217/bmm-2021-0455 ◽

2021 ◽

Author(s):

Yahya H Hobani

Keyword(s):

Therapeutic Target ◽

Multiple Cancer ◽

Phosphatase And Tensin Homolog ◽

Tensin Homolog ◽

Non Coding Rna ◽

Potential Biomarker ◽

Noninvasive Biomarker ◽

Cancer Types ◽

Molecular Therapeutic ◽

Long Non Coding Rna

Deregulation of long non-coding RNAs (lncRNAs) has been implicated in tumorigenesis. FALEC is a lncRNA upregulated in multiple cancer types. FALEC functions as an oncogene through various mechanisms, such as competitively binding miRNAs and regulation of PI3K/AKT, Tp53 and phosphatase and tensin homolog signaling pathways. Pertinent to clinical practice, the use of FALEC as a putative biomarker has been identified. These findings suggested that FALEC might play a pivotal role in human cancers. Further studies are warranted to examine the diagnostic and prognostic performance of FALEC as a noninvasive biomarker in liquid biopsy samples and promote its development to be a clinically utilizable prognostic cancer biomarker and molecular therapeutic target.

Download Full-text

CASC15：A tumor-associated long non-coding RNA

Current Pharmaceutical Design ◽

10.2174/1381612826666200922153701 ◽

2020 ◽

Vol 26 ◽

Author(s):

Bei Wang ◽

Wen Xu ◽

Yuxuan Cai ◽

Chong Guo ◽

Gang Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Therapeutic Target ◽

Cancer Colorectal ◽

Tumor Development ◽

Pathophysiological Mechanism ◽

Biological Processes ◽

Non Coding Rna ◽

Cancer Côlon ◽

The Relationship ◽

Long Non Coding Rna

Background: CASC15, one of long non-coding RNA, is involved in the regulation of many tumor biological processes, and is expected to become a new biological therapeutic target. This paper aims to elucidate the pathophysiological function of CASC15 in various tumors. Methods: The relationship between CASC15 and tumors was analyzed by searching references, and summarizes the specific pathophysiological mechanism of CASC15. Results: LncRNA CASC15 is closely related to tumor development, and has been shown to be abnormally high expressed in all kinds of tumors, including breast cancer, cervical cancer, lung cancer, hepatocellular carcinoma, gastric cancer, bladder cancer, colon cancer, colorectal cancer, cardiac hypertrophy, intrahepatic cholangiocarcinoma, leukemia, melanoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma. However, CASC15 has been found to be downexpressed abnormally in ovarian cancer, glioma and neuroblastoma. Besides, it is identified that CASC15 can affect the proliferation, invasion and apoptosis of tumors. Conclusion: LncRNA CASC15 has the potential to become a new therapeutic target or marker for a variety of tumors.

Download Full-text

Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma

Experimental and Molecular Pathology ◽

10.1016/j.yexmp.2021.104638 ◽

2021 ◽

pp. 104638

Author(s):

Chao Guo ◽

Shuhuang Zhou ◽

Weimin Yi ◽

Pingzhou Yang ◽

Ou Li ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Therapeutic Target ◽

Antisense Rna ◽

Prognostic Biomarker ◽

Non Coding Rna ◽

Long Non Coding Rna

Download Full-text

Long non-coding RNA (lncRNA): A potential therapeutic target in acute lung injury

Genes & Diseases ◽

10.1016/j.gendis.2021.07.004 ◽

2021 ◽

Author(s):

Almaz Zaki ◽

M Shadab Ali ◽

Vijay Hadda ◽

Syed Mansoor Ali ◽

Anita Chopra ◽

...

Keyword(s):

Acute Lung Injury ◽

Lung Injury ◽

Therapeutic Target ◽

Potential Therapeutic Target ◽

Non Coding Rna ◽

Long Non Coding Rna

Download Full-text

miR-27b Suppresses Endothelial Cell Proliferation and Migration by Targeting Smad7 in Kawasaki Disease

Cellular Physiology and Biochemistry ◽

10.1159/000492354 ◽

2018 ◽

Vol 48 (4) ◽

pp. 1804-1814 ◽

Cited By ~ 9

Author(s):

Xing Rong ◽

Donghui Ge ◽

Danping Shen ◽

Xianda Chen ◽

Xuliang Wang ◽

...

Keyword(s):

Endothelial Cell ◽

Kawasaki Disease ◽

Therapeutic Target ◽

Umbilical Vein ◽

Luciferase Reporter ◽

Endothelial Cell Proliferation ◽

Cell Functions ◽

Potential Biomarker ◽

And Migration ◽

Proliferation And Migration

Background/Aims: Increasing evidence indicates that microRNAs (miRNAs) play important roles in Kawasaki disease (KD). Our previous study demonstrated that hsa-miR-27b-3p (miR-27b) was up-regulated in KD serum. However, the specific role of miR-27b in KD remains unclear. We aimed to investigate that miR-27b could be a biomarker and therapeutic target for KD treatment. As well, the specific mechanism of miR-27b effecting endothelial cell functions was studied. Methods: The expression of miR-27b and Smad7 was measured by qRT-PCR. Gain-of-function strategy was used to observe the effect of miR-27b on human umbilical vein endothelial cells (HUVECs) proliferation and migration. Bioinformatics analyses were applied to predict miR-27b targets and then we verified Smad7 by a luciferase reporter assay. Western blot was performed to detect the protein expression of Smad7, PCNA, MMP9, MMP12 and TGF-β-related genes. Results: We confirmed that miR-27b was shown to be dramatically up-regulated in KD serum and KD serum-treated HUVECs and that elevated expression of miR-27b suppressed the proliferation and migration of HUVECs. Furthermore, our results verified that miR-27b mediated cell functions by affecting the TGF-β via targeting Smad7 in HUVECs. Conclusion: These results suggested that up-regulated miR-27b had a protective role in HUVECs proliferation and migration via targeting Smad7 and affecting TGF-β pathway. Therefore, miR-27b represented a potential biomarker for KD and may serve as a promising therapeutic target for KD treatment.

Download Full-text

MiR-29a: a potential therapeutic target and promising biomarker in tumors

Bioscience Reports ◽

10.1042/bsr20171265 ◽

2018 ◽

Vol 38 (1) ◽

Cited By ~ 10

Author(s):

Jin-yan Wang ◽

Qian Zhang ◽

Dan-dan Wang ◽

Wei Yan ◽

Huan-huan Sha ◽

...

Keyword(s):

Cell Proliferation ◽

Therapeutic Target ◽

Therapeutic Strategy ◽

Transcriptional Level ◽

Additional Insight ◽

Potential Therapeutic Target ◽

Rna Molecules ◽

Non Coding Rna ◽

Non Coding Rnas ◽

Novel Therapeutic

MiRNAs, small non-coding RNA molecules, were recognized to be associated with the incidence and development of diverse neoplasms. MiRNAs were small non-coding RNAs that could regulate post-transcriptional level by binding to 3′-UTR of target mRNAs. Amongst which, miR-29a was demonstrated that it had significant impact on oncogenicity in various neoplasms through binding to critical genes which enhanced or inhibited the progression of cancers. MiR-29a participated in kinds of physiological and pathological processes, including virus replication, cell proliferation, differentiation, apoptosis, fibrosis, angiogenesis, tumorigenicity, metastasis, drug-resistance, and so on. According to its sufficient sensitivity and specificity, many studies showed that miR-29a might serve as a potential therapeutic target and promising biomarker in various tumors. In this review, we discussed the functions of miR-29a and its potential application in the diagnosis, treatment and stages of carcinoma, which could provide additional insight to develop a novel therapeutic strategy.

Download Full-text